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Differentiated thyroid carcinoma (DTC), which develops from thyroid follicular cells, includes 
both papillary and follicular thyroid carcinomas (PTC and FTC). Although the incidence of 
pediatric DTC is increasing, it is an uncommon disease, affecting approximately 10 children 
(≤18 years) annually in the Netherlands, compared with more than 700 adults (1–5). Due to 
this low incidence, randomized prospective studies have not been performed in children 
(6). In most pediatric patients with DTC specific risk factors cannot be identified, although 
in a subset of patients radiation exposure has been recognized as predisposing to this 
disease (6). Pediatric DTC is sometimes associated with genetic syndromes, and has also 
been observed in children from families with familial non-medullary thyroid cancer (7). 
Compared to adults, children often present at a more advanced tumor stage and 
show higher recurrence rates (8,9). Nevertheless, the prognosis of childhood-onset DTC 
is excellent, with 15-year survival rates higher than 95%, thus even more favorable than in 
adults (2,10). 
The initial treatment for patients with pediatric DTC consists of (near) total thyroidectomy 
with or without additional lymph node dissection. In the majority of patients surgical 
treatment is followed by ablation therapy with radioactive iodine (131-I). During follow-up, 
TSH suppressive therapy has for years been applied to diminish the risk of recurrent disease 
(11,12). However, recent years have seen increasing discussion as to whether the benefits 
of 131-I administration and TSH suppressive therapy outweigh the risk of possible adverse 
effects. Therefore, at present, 131-I administration often depends on risk stratification, 
and the use of TSH suppressive therapy is tempered in pediatric patients who show no 
evidence of disease (13,14). However, recommendations are based mainly on findings in 
adult patients, as data on pediatric DTC patients regarding (long-term) effects of 131-I 
treatment, long-term TSH suppressive therapy, and quality of life are limited. 
Studies on the genetic background of sporadic pediatric DTC have shown alterations 
that induce dysregulation of the mitogen-activated protein kinase (MAPK) signaling pathway 
(15,16). In pediatric patients with sporadic PTC, mainly gene fusions are encountered (16). 
Dysregulation of microRNAs (miRNAs), which are small (18-24 nucleotides), endogenous 
non-coding RNAs that post-transcriptionally regulate gene expression, is related to cancer 
development in different tumor types including thyroid cancer (17). Thus, miRNA analysis 
may be a useful method to confirm the diagnosis of thyroid carcinoma and to differentiate 
between DTC subtypes. However, the expression of miRNAs in pediatric DTC has yet to 
be assessed.
In this thesis we aimed to evaluate the outcome, surgical complications, and late 
effects of 131-I treatment and TSH suppressive therapy, as well as quality of life, in 
survivors of pediatric DTC treated in the Netherlands. In this patient group, we also aimed 
to evaluate the presence of somatic genetic alterations, and their relationship with clinical 
presentation and long-term outcome, as well as miRNA expression. Detailed insight into 
outcome and treatment-related damage is needed to improve evidence-based treatment 
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and follow-up strategies. Knowledge about the predictive value of the genetic alterations 
in thyroid tumors could support the choice of more patient-tailored treatment.
In chapter 1 we provided a general introduction and outlined the aims of this thesis. In 
chapter 2 we evaluated the presentation, surgical complications, and long-term outcome 
in patients with pediatric DTC. We also assessed the presence and type of second 
malignant neoplasms (SMNs) in these patients. A study in the United States reported 
complication rates of thyroid surgery to be higher in children than in adults (18). Outcomes 
were optimized when surgeries were performed by high-volume surgeons. Data on 
the development of SMNs after 131-I administration in children are scarce (19,20). In 
adults, although several studies reported an increase in SMNs after 131-I for thyroid cancer 
(21–23), others could not confirm these data (10,24). In a nationwide study we identified 
170 patients with pediatric DTC treated in the Netherlands between 1970 and 2013. 
Overall survival was 99.4% after a median follow-up of 13.5 years (range 0.3-44.7 years); 
one patient with familial adenomatous polyposis and a PTC with lung metastases died at 
the age of 20 years due to complications of his colon carcinoma. Extensive follow-up data 
were available for 105 patients (83.3% females). The median age at diagnosis was 15.6 
years (range 5.8-18.9 years). PTC was diagnosed in 81.0% of the patients and 19.0% had 
FTC. Upon initial diagnosis, 43.8% of the patients had metastases to the cervical lymph 
nodes and 13.3% had distant metastases, mainly to the lungs. All patients underwent 
total thyroidectomy and 97.1% were treated with 131-I, with a median cumulative activity 
of 5.66 GBq (range 0.74-35.15 GBq). The patients were treated in 39 different hospitals. 
Life-long postoperative complications (i.e. permanent hypoparathyroidism and/or 
recurrent laryngeal nerve injury) occurred in almost one-third of the patients. At last known 
follow-up, 8.6% of the patients had persistent disease and 7.6% experienced a recurrence. 
These recurrences were not associated with TSH suppression. SMNs after pediatric DTC 
were found in three patients, two of whom developed breast cancer. 
In chapter 3 we assessed the long-term effects of 131-I on salivary gland function 
(SGF) in survivors of pediatric DTC, and the prevalence of salivary gland dysfunction 
(SGD) in relation to patient and 131-I treatment characteristics in this group. We also 
evaluated xerostomia complaints in relation to salivary flow rates. In adults, it has been 
shown that 131-I treatment may reduce SGF (25). The uptake of 131-I through the sodium-
iodine transporter (NIS) in the salivary gland striated ducts is most likely responsible for 
the adverse effects of 131-I on the salivary glands (26). As data regarding SGF after 131-I 
administration in pediatric patients with DTC are limited, we therefore assessed the SGF by 
sialometry, sialochemistry, and a xerostomia (subjective feeling of a dry mouth) inventory 
in long-term survivors of pediatric DTC. We included 65 survivors in the analyses. SGD, 
defined as an unstimulated whole saliva flow of <0.2 mL/min or a stimulated whole saliva 
flow <0.7 mL/min, was present in 47.6% of this group. A higher cumulative 131-I activity 
was associated with decreased stimulated salivary secretion. Furthermore, one in three 
survivors reported moderate to severe complaints of xerostomia, again related to higher 
cumulative administrations of 131-I.   
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TSH suppressive therapy leads to subclinical hyperthyroidism. Possible adverse effects 
of long-term subclinical hyperthyroidism on cardiac function are increasingly being 
recognized (27,28). In chapter 4 we studied the prevalence of cardiac dysfunction in 
long-term adult survivors of pediatric DTC in relation to treatment variables including 
TSH level during follow-up, the association between cardiac dysfunction and plasma 
biomarkers, and the prevalence of atrial fibrillation (AF) in this patient group. Cardiac 
assessments were performed in 66 survivors and included echocardiography, measurement 
of plasma biomarkers (N-terminal pro-brain natriuretic peptide, high-sensitive Troponin-T, 
galectin-3), and 24-hour Holter electrocardiography. Reference data for echocardiography 
were derived from the recommendations of the American Society of Echocardiography 
(29–31). Echocardiographic measurements were also compared with retrospective data of 
66 unaffected sex- and age-matched Dutch controls. The median follow-up was 17 years. 
Regarding the left ventricular (LV) systolic function, LV ejection fraction <50% was found 
in one survivor, and median global longitudinal systolic strain was nearly normal. Diastolic 
dysfunction, according to a strict definition, was present in 14 asymptomatic survivors 
(21.2%) when compared with reference values from literature (29). Overall, diastolic 
function of survivors was lower than that of controls (e’mean 14.5 versus 15.8 cm/s, 
P = 0.006). A higher attained age and larger waist circumference were associated with 
decreased diastolic function, whereas TSH levels and cumulative administered radioiodine 
dose were not. In the survivors, biomarkers were not associated with diastolic dysfunction, 
and AF was not observed. 
In chapter 5 we evaluated generic health-related quality of life (HRQoL), fatigue, 
anxiety, and depression in long-term survivors of pediatric DTC compared with age- 
and gender-matched controls, and assessed thyroid cancer-specific HRQoL in survivors. 
Sixty-seven survivors and 56 controls were evaluated using the Short Form 36 (SF-36), 
Multidimensional Fatigue Inventory 20 (MFI-20), and Hospital Anxiety and Depression 
Scale (HADS). Survivors also completed the thyroid cancer-specific HRQoL questionnaire 
(THYCA-QoL). Median follow-up was 17.8 years. We found overall normal HRQoL, fatigue, 
anxiety, and depression in the survivors compared to the matched controls. However, 
survivors reported more physical problems, role limitations due to physical problems, 
and mental fatigue. Thyroid cancer-specific complaints (mainly neuromuscular, throat/
mouth, psychosocial, and sensory problems) were reported by some survivors, but 
the majority reported few or no complaints. More extensive treatment characteristics and 
unemployment were most frequently associated with lower QoL. 
 In chapter 6 we analyzed thyroid tissues of 85 pediatric DTC patients to evaluate 
the presence of somatic BRAF mutations and RET/PTC rearrangements, and their 
relationship with clinical presentation and long-term outcome in pediatric patients with 
PTC. We also assessed the expression of miRNA-146b, -221 and -222 in pediatric patients 
with DTC. RET/PTC rearrangements and classical BRAFV600E mutations were present in, 
respectively, 21.7% and 5.8% of the patients with histologically confirmed PTC. These 
gene alterations were associated neither with the initial tumor staging (TNM classification) 
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nor the clinical outcome. A significant association was found between increased expression 
of miRNA-146b, -221 and -222 and the diagnosis of PTC. Analysis of miRNA expression 
may therefore be helpful for establishing the diagnosis of PTC in pediatric patients.
General  d iscuss ion and future perspect ives
Despite the frequent presence of cervical lymph node and distant metastases, pediatric 
patients with DTC have an excellent long-term survival rate, generally because of well 
differentiated tumors and the availability of effective therapy (2). However, in a large single 
center study performed in the United States, the excellent survival in children was followed 
by a later death from a non-thyroid malignancy, found to be a cause of death in 68% of 
patients who died 30 to 50 years after initial diagnosis. Most of these cases had undergone 
antecedent irradiation (131-I or external beam therapy) (8). Our nationwide study (chapter 
2) and a recent multicenter review from the United Kingdom (32) have confirmed 
the excellent survival in this patient group, but the median durations of follow-up were too 
short (13.5 and 14.1 years, respectively) to evaluate excess mortality later in life.
To safeguard the excellent long-term survival of pediatric DTC, it is vital to prevent 
early and late adverse events of treatment. However, long-term follow-up data of 
pediatric DTC patients, especially on treatment-related complications, are scarce. Over 
recent years, the occurrence of adverse events after cancer treatment have gained more 
attention. In this chapter, we will first discuss the surgical complications of treatment and 
late effects of 131-I administration and TSH suppressive therapy. We will then address 
recent developments in thyroid pathology. After that we will explore the knowledge gaps 
regarding pediatric DTC, and future directions for research possibilities. Finally, we will 
discuss ways to improve the organization of care for pediatric patients.  
Surgical complications 
Total thyroidectomy, recommended for the majority of pediatric patients with DTC, is 
associated with a higher complication risk than partial thyroidectomy, particularly when 
total thyroidectomy is combined with lymph node dissection (13,14,18,33). In our cohort, 
all patients underwent total thyroidectomy. Using strict definitions, we found transient 
and permanent hypoparathyroidism in 15.2% and 23.8% of the patients, respectively. 
This is relatively high when compared with other cohorts of children treated for DTC 
(7.4%-32.7% for transient and 0%-32% for permanent hypoparathyroidism, respectively) 
(20,34–37). In our cohort, the occurrence of recurrent laryngeal nerve injury was 12.4%, 
which is within the ranges of other pediatric cohorts (0%-40%) (35,38). As definitions of 
surgical complications in the literature are heterogeneous, the reported complication 
rates vary widely and are therefore problematic to compare. Moreover, patients in our 
cohort were surgically treated in 39 different hospitals. This scattered treatment may have 
contributed to our complication rates. Because of the low number of surgical treatments 
per hospital in our cohort we were unable to analyze differences in the occurrence of 
surgical complications between high- and low-volume centers. However, complications of 
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thyroid surgery in pediatric patients have shown to be reduced when surgery is performed 
by high-volume surgeons (18,39). We therefore regard centralization of care for pediatric 
patients to be crucial. This will be discussed below (see Organization of care). 
Late effects of 131-I therapy
Ablation therapy with radioiodine has long been part of standard DTC treatment, and 
is effective because thyroid cells specifically take up (radio)iodine. Thereby, it is one of 
the oldest targeted therapies in oncology. However, in recent years the possible adverse 
effects of radioiodine administration have been increasingly acknowledged. In children, as 
compared to adults, the effects of 131-I may be amplified, as 131-I activity is distributed 
over a smaller body and accumulates in cells that have increased potential to proliferate. 
In this section we will focus on effects of 131-I administration on the salivary glands, bone 
marrow, fertility, and development of second malignant neoplasms. 
Salivary gland dysfunction
Saliva is vital for maintaining oral health (40). The striated ducts of the salivary gland express 
NIS, and are therefore able to concentrate iodine selectively (26). This mechanism is most 
likely responsible for the SGD and the xerostomia complaints described in this thesis, which 
we found in respectively almost half and one-third of the long-term survivors of pediatric 
DTC. Both SGD and xerostomia were related to a higher cumulative administration of 
131-I. These effects may be interpreted as permanent damage to the salivary glands, as 
they were observed in survivors after a median follow-up of 11 years. Regarding the salivary 
composition, in survivors of pediatric DTC the levels of total protein and amylase were 
reduced, as compared to reference values from non-affected individuals. This indicates 
that SGF remains impaired many years after treatment. We postulate that the β-radiation, 
emitted due to the accumulation of 131-I in the salivary glands, directly affects the salivary 
gland stem cells, resulting in a reduced regenerative potential (41).  
In the literature, only one other study, by Albano et al., evaluated SGD after 131-I 
administration in pediatric patients with DTC (42). Albano’s study reports SGD in 1.9% of 
the survivors, versus 47.6% in our study. This difference could be explained by the methods 
used, as Albano et al. used qualitative data from retrospectively assessed medical records 
and did not specify their definition of SGD (28,43). 
At the time that pediatric patients in our study were treated, fixed 131-I activities 
were standard and generally similar to those used in adult patients. Thus the survivors 
of pediatric DTC in our study received relatively higher activities of 131-I per kilogram of 
body weight compared to adults. They were, moreover, treated during a period of growth 
and development. The long-term SGD found in our study, related to cumulative 131-I 
administration, emphasizes the need for more patient tailored 131-I dosage for children. 
Recommendations to prevent salivary gland damage after 131-I treatment include 
generous intake of fluids, use of gustatory sialogogues (e.g. lemon juice, candy), and 
gland massage (28). However, whether sialogogues should be used immediately after 131-I 
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administration remains controversial (44,45). Patients who used sialogogues soon after 
131-I therapy were found to have a decreased radioiodine absorption in the parotid glands 
(46,47). Conversely, others proposed that early initiation of sialogogues increases salivary 
gland blood flow, and thereby 131-I exposure (28,43,48). Up till now, the treatment of 
sialadenitis after 131-I administration in most cases still involves the intake of high volumes 
of fluid and administration of sialogogues. Anti-inflammatory drugs are also proposed, 
as well as sialendoscopy (28). Furthermore, withdrawal of thyroid hormone, which is part 
of the preparation for 131-I treatment, causes a transient decrease of renal function, 
and thereby a slower renal clearance of 131-I. The use, instead, of recombinant human 
thyroid-stimulating hormone (rhTSH), prevents the impairment of renal function, which 
may theoretically reduce salivary gland toxicity (49). However, for adult patients, rhTSH 
is applied particularly in ablative therapy, and not used in consecutive 131-I treatment. 
Furthermore, because it is not a standard treatment for children, it is not an alternative in 
the prevention of salivary damage. 
Our findings emphasize the need for surveillance of possible salivary gland dysfunction 
during follow-up in pediatric patients with DTC. In case of xerostomia-related complaints, 
referral to a dentist or an oral medicine specialist should be considered at an early 
stage, to prevent caries and maintain quality of life. In general, the importance of good 
oral hygiene should be discussed before start of therapy. We therefore propose to 
include recommendations for oral care, including regular dental hygienist visits, as part 
of the standard treatment and follow-up of pediatric patients with DTC. Importantly, 
the 131-I activity to be administered should be weighed very carefully to prevent salivary 
gland damage.  
Bone marrow suppression
Another effect reported after 131-I therapy is transient bone marrow suppression (50). This 
is manifested by a transient reduction in leukocyte and/or, more frequently, platelet count 
three to five weeks after 131-I administration. In a population of adult patients with DTC, 
the cumulative 131-I dose was independently associated with thrombocytopenia (50). 
Post-treatment platelets and leukocytes, which were transiently decreased compared to 
pre-treatment values, normalized to baseline levels 5 years after treatment. This suggests 
that in most adult patients the clinical effects of bone marrow toxicity are limited. As part 
of our nationwide study, we evaluated blood counts in long-term survivors of pediatric 
DTC. Leukocytes and platelet levels were within the reference ranges (data not shown). 
These findings are in line with the findings in adults (51). However, patients with multiple 
bone metastases treated with high cumulative 131-I dosages may develop severe bone 
marrow toxicity, which might lead to myelodysplasia or aplastic anemia (52). Leukemia has 
been described in adult patients with multiple bone metastases who received more than 
18.5 GBq (500 mCi) 131-I (20). One case report described chronic myeloid leukemia in 
a child, following treatment of thyroid cancer (53–55). 




Whether 131-I administration has adverse effects on fertility remains a subject of debate. 
Up to one year after treatment a higher incidence of miscarriages and transient amenorrhea 
or irregular menses have been shown in adult patients with DTC (56,57). Also, a transient 
decrease has been reported in the levels of Anti-Müllerian Hormone (AMH, a marker 
for ovarian reserve) (55,58). Long-term effects of 131-I on ovarian function seem to be 
limited to a slightly earlier onset of menopause in adult DTC survivors (59). In our cohort 
of long-term female survivors of pediatric DTC, we found no abnormalities in fertility 
based on evaluation of fertility outcomes, parameters of reproductive health, indications 
of impaired fertility, and AMH (42,60). Previous studies in survivors of pediatric DTC were 
limited by lack of definitions and a small number of patients (61,62). Fertility is represented 
by reproductive characteristics (number of pregnancies, pregnancy outcomes, health of 
offspring), gonadal function and serum AMH level. The latter is commonly used as a marker 
for ovarian reserve in studies with cancer survivors, as the AMH level is not influenced by 
the menstrual cycle (63). However, consensus on the clinical value of AMH is lacking (64). 
Although overt hyperthyroidism can lead to disturbances in the menstrual cycle (65,66), 
the effects of the subclinical hyperthyroidism resulting from TSH suppressive therapy are 
less well established (67,68). Therefore, subclinical hyperthyroidism may only have limited 
effects on fertility in female survivors of pediatric DTC. 
In males, the germinal epithelium, and particularly the spermatogonia within it, are very 
sensitive to the effects of radiation (69,70). Transient elevation of serum follicle-stimulating 
hormone (FSH) and reduction in sperm motility have been reported following 131-I therapy 
(71). One study reported that 33% of males treated during adulthood had oligospermia 
after high cumulative 131-I activities (13). These data have resulted in recommendations to 
preserve semen of post-pubertal males who are expected to receive 14.8 GBq (400 mCi) 
131-I (13,72). A more recent study in adult DTC patients showed a significant increase in 
FSH and a decrease in inhibin B levels 3 months after administration of a single 131-I activity 
of 3.7 Gbq (100 mCi) compared with pre-treatment values. Also, sperm concentrations 
and the percentage of morphologically normal spermatozoa were transiently decreased 
3 months after 131-administration. The authors propose sperm preservation for DTC 
patients requiring 131-I activities higher than 3.7 Gbq, a recommendation more cautious 
than the current guidelines on pediatric DTC (11,12). As the incidence of pediatric DTC 
in boys is very low, international collaboration is needed to study the effects of 131-I 
administration on fertility in male survivors of pediatric DTC.  
Second malignant neoplasms
In the cohort described in this thesis, three female patients developed a second malignant 
neoplasm (SMN) during follow-up of pediatric DTC (supplemental data of chapter 2). Two 
had received 131-I before development of the SMN, which in both cases was breast cancer. 
The respective cumulative 131-I activities administered to these patients were 8.33 GBq 
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(225 mCi) and 35.15 GBq (950 mCi). During follow-up, the patient who received 35.15 GBq 
developed two recurrences, for which she was treated with 131-I. Although, especially in 
the latter patient, the cumulative administered 131-I activities were relatively high, patient 
numbers are too low to draw conclusions regarding causality. In the literature, several 
studies reported an increase of SMNs in adult patients treated with 131-I for thyroid cancer 
(21). An increased risk for second malignancies was found after administration of higher 
cumulative dosages (10,24). However, others did not confirm these data (73). Verkooijen 
et al. described an overall increased standardized incidence rate for SMNs in DTC 
patients, either preceding or following thyroid cancer diagnosis, but not specifically for 
SMNs following 131-I administration (19,20,42). This finding suggests that these patients 
may have had a genetic predisposition for the development of malignancies. The cases 
described in this thesis add to the sparse data on SMNs in survivors of pediatric DTC (11). 
Late effects of TSH suppressive therapy
During follow-up, TSH suppressive therapy has for years been advocated to diminish 
the risk of recurrent disease (74,75). However, as TSH suppression induces an iatrogenic 
(subclinical) hyperthyroid state, it may cause adverse effects. In particular it may affect 
the skeletal and cardiovascular systems (27). In 524 adult patients with DTC, a 3.3-fold 
increased risk of cardiovascular mortality was found. Each 10-fold decrease in geometric 
mean TSH level was associated (independently) with a 3.1-fold greater risk of cardiovascular 
mortality (76,77). 
Bone mineral density and growth 
Normal euthyroid status is essential for skeletal development, growth and maintenance of 
adult bone mass and strength (77). Thyroid hormone receptor α (TRα) is the main thyroid 
hormone receptor expressed in bone. It mediates the action of triiodothyronine (T3) on 
bone and cartilage (77). During childhood, thyroid hormones stimulate bone growth and 
mineralization. Although rare in children, thyrotoxicosis accelerates skeletal development 
and bone mineral deposition, which may result in premature fusion of the growth plates, 
thereby leading to reduced height (78). Conversely in adults T3 stimulates bone loss (78). 
TSH has also been proposed to be involved in bone turnover by binding directly to TSH 
receptors on osteoblasts and osteoclasts. However, to date, the underlying mechanisms 
by which TSH may affect the skeleton are not completely understood (79,80). 
In adult pre-menopausal women and in men, two systematic literature reviews showed 
little or no effect of TSH suppressive therapy with levothyroxine on BMD (77). In post-
menopausal women on TSH suppressive therapy, data are conflicting, but this group may 
in general be at risk of bone loss and osteoporosis (81,82). 
Few studies have been performed on the late effects of TSH suppressive therapy during 
childhood on bone mineral density (BMD) and target height. Although two cross-sectional 
studies in survivors of pediatric DTC showed no effects on BMD (83), cross-sectional 
designs do not allow exploration of changes in BMD over time. Moreover, other factors 
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like gender and age may influence BMD (84). It is worth noting that, as described in this 
thesis (chapter 2), a significant number of pediatric patients with DTC experience surgical 
complications including hypoparathyroidism, which may lead to an increased BMD, 
but also may result in atypical bone structure and bone turnover (29). Recognizing that 
evaluation of possible intra-individual BMD changes in pediatric DTC survivors would be 
of great value, we have therefore collected these data as part of this study. The first BMD 
measurements were performed between 2012 and 2014, and the second measurements 
are currently under evaluation. 
Cardiovascular morbidity
In our cohort, we found diastolic dysfunction in 21.2% of survivors of pediatric DTC when 
compared with reference values from literature (85). Survivors with diastolic dysfunction 
had a median age of 37.9 years. As diastolic function declines with age, our findings 
may indicate early cardiac aging in asymptomatic survivors. This finding is of interest, 
as diastolic dysfunction may be the first manifestation of more overt heart failure (85). 
Longitudinal measurements are needed to explore the course of the diastolic function, 
and the potential clinical consequences of diastolic dysfunction, found at an early age 
in a subset of the survivors of pediatric DTC. In our cohort of survivors of pediatric DTC, 
a higher attained age and larger waist circumference were associated with decreased 
diastolic function; these are established risk factors for diastolic dysfunction (86). However, 
in our cohort, TSH levels and cumulative administered radioiodine dose were not associated 
with a decrease in diastolic function. Yet an association between TSH suppression and 
diastolic dysfunction has previously been reported in adult survivors of DTC (87). These 
different findings may be explained by the younger age of the survivors in our cohort. 
Furthermore, in the two studies the definitions and statistical approach to measuring TSH 
during follow-up are not fully comparable. 
According to traditional risk classifications like the Systematic Coronary Risk Evaluation 
(SCORE), younger persons, i.e. the majority of survivors of pediatric DTC in our cohort, 
would be classified as having a low (absolute) risk of developing coronary heart disease 
and stroke death (88). Among adult thyroid cancer survivors, however, it has been reported 
that 9.7%, 6.9% and 19.1% developed cardiovascular disease after respectively <10 years, 
10-20 years, and >20 years of follow-up (patient self-reported data) (89,90). Early treatment 
of cardiovascular damage might be more beneficial than preventive interventions in 
the few years preceding a cardiovascular event (13,14,91,92). Therefore, while awaiting 
the results of follow-up studies, the assessment and treatment of cardiovascular risk factors 
may be considered in survivors of pediatric DTC.
The use of TSH suppressive therapy is currently tempered in both adult and pediatric 
patients who have long term disease free survival (93). In the majority of adult patients 
with DTC, more profound TSH suppression has been shown to provide little or no benefit 
(94,95). Moreover, improvement of techniques for detection and treatment of residual or 
recurrent disease might diminish the need for aggressive TSH suppression. However, as 
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long as data regarding the effect of tempered TSH suppression on long-term oncological 
outcomes are limited in adults - and altogether lacking in pediatric patients - close 
monitoring of the latter patients remains necessary.
Quality of life
Although diagnosis and treatment of pediatric DTC constitute a major life event, we 
found overall normal HRQoL, fatigue, anxiety, and depression scores in long-term 
survivors of pediatric DTC, compared to matched controls. Survivors of pediatric DTC 
more frequently showed physical problems, role limitations due to physical problems, and 
mental fatigue, but survivors’ overall scores on these domains were still within the normal 
range. Furthermore, although some survivors reported thyroid cancer-specific complaints, 
the majority had few or no complaints. These results correspond with the normal QoL 
described in survivors of adolescent DTC (96), and with the finding of similar achievement 
of psychosocial developmental milestones (social, autonomy, and psychosexual domains) 
in long-term survivors of pediatric DTC compared with controls (97–99). As for impaired 
physical functioning of survivors compared to controls, this has also been described in 
survivors of other childhood cancers, as well as in survivors of adult DTC (100). Although 
mental fatigue in survivors of (adult) DTC has been proposed to be related to suboptimal 
TSH levels (94,101), we did not find a relation between TSH and fatigue. Furthermore, 
other groups also reported impaired HRQoL to be independent of TSH level (102). 
Although we reported an overall normal QoL in survivors of pediatric DTC, the QoL 
scores varied more among survivors compared to controls; the survivors relatively more 
often reported lower QoL. In our study, lower QoL was associated with unemployment 
and more extensive treatment characteristics. These data underscore the need for 
an individual approach of these patients and the importance of identifying vulnerable 
patients at an early stage so as to provide adequate psychological care. For this purpose, 
assessment of QoL should be implemented during follow-up, as is also advised by 
the Dutch Childhood Oncology Group (DCOG) (102). For the study described in this 
thesis, we selected both widely used questionnaires (Short Form 36, Multidimensional 
Fatigue Inventory 20 and Hospital Anxiety and Depression Scale) and a thyroid cancer 
specific questionnaire (THYCA-QoL). These questionnaires were chosen with the aim of 
comparing our data with the available literature, as well as for gathering information on 
disease specific problems. The DCOG advises using the General Health Questionnaire 
28 (GHQ-28, in our study used for screening) and the Short Fatigue Questionnaire (in 
Dutch: Verkorte Vermoeidheidsvragenlijst) for all adult childhood cancer survivors (103). 
For survivors of pediatric DTC, we suggest adding a disease specific questionnaire to 
identify thyroid cancer-specific problems, like voice problems. Physicians are often known 
to underestimate the incidence of thyroid cancer-specific complaints in DTC survivors 
(104). Thus, the implementation of QoL questionnaires in care paths may help to detect 
complaints and improve quality of care for pediatric DTC survivors.




We reassessed the histology of all formalin-fixed paraffin-embedded (FFPE) tissues of 
the pediatric DTC patients included in chapter 6, i.e. all patients who gave informed 
consent for reassessment of their tissue and of whose FFPE material was available for this 
study. It is remarkable that the reassessed histopathological diagnosis was less frequently 
an FTC compared to the initial diagnosis (2.4% vs. 17.6%). Also, during reassessment, in 
two patients (2.4%) we found only an adenoma, and in 6 patients (7.1%) the diagnosis was 
ambiguous. These differences may be explained by the fact that only a selection of FFPE 
blocks were available for reassessment. Although representative material was requested 
and, where possible, the same blocks in which the tumor was described in the original 
pathology report were used for reassessment, the lesions on the FFPE blocks available 
to us may not necessarily have been the same as those reported by the pathologists who 
made the initial diagnosis. Another explanation may be that, as pediatric DTC occurs 
infrequently, pathologists having extensive experience with this disease are more familiar 
with the interpretation and classification of DTC histology. Finally, during reassessment 
poorly differentiated thyroid carcinoma (PDTC) was diagnosed in 6 patients (7.1%), three 
of whom were initially diagnosed with a (micro) PTC and three with an FTC. PDTC was 
for the first time included in the 2004 edition of the WHO classification of thyroid tumors 
(16). This may explain the absence of initial diagnoses of PDTC in our cohort, although 
two patients found to have a PDTC during reassessment were diagnosed after 2004. As 
studies in pediatric patients with thyroid cancer are limited and PDTC is still a relatively 
new diagnosis, data on the incidence of PDTC during childhood are scarce. 
Between children and adults the biological behavior of DTC differs considerably. 
This may be explained by differences in genetic alterations. We observed somatic RET/
PTC rearrangements and BRAFV600E mutations in only 23.5% of the patients in our cohort, 
suggesting that many other alterations are involved. This has recently been confirmed and 
updated by Cordioli et al., who studied the prevalence of RET/PTC1, RET/PTC2, RET/PTC3, 
BRAFV600E, ETV6-NTRK3, AGK-BRAF, and NRASQ61 in primary thyroid tumors of 35 pediatric 
PTC patients (105). Mutations were detected in 20 out of 35 PTC cases (57%): RET/PTC 
rearrangements in 13 (37%), BRAFV600E mutations in 3 (9%), ETV6-NTRK3 in 3 (9%), and 
AGK-BRAF in 4 (11%). In another series these researchers showed that AGK-BRAF fusions 
were associated with distant metastases and younger age, and the BRAFV600E mutation was 
associated with a larger tumor size and older age (16). In 43% of the 35 patients described 
by Cordioli et al. no genetic event was identified, which suggests that other (epi)genetic 
factors may be associated with the pathogenesis and biological behavior of these tumors 
(106). These factors still need to be unraveled. 
We have shown increased expression of miRNA-146b, -221 and -222 to be significantly 
associated with PTC diagnosis; this may be helpful for establishing the diagnosis of PTC in 
pediatric DTC cases. Moreover, Liang et al. confirmed in their meta-analysis that miRNA-
221/222 may significantly improve accuracy in the diagnosis of thyroid cancer (107). 
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The assessment of miRNA may also be of value for understanding the clinical behavior 
of thyroid tumors as has been illustrated by Li et al., who showed a high expression of 
miRNA-146b-5p in thyroid cancer tissue of patients with histological features of Hashimoto 
thyroiditis. The level of expression of miRNA-146b-5p was associated with TNM stage (7).
A diagnosis of thyroid cancer during childhood raises the question of hereditability. In 
pediatric DTC patients an increased risk of second primary tumors is present (7). Although 
these second malignancies are easily ascribed to 131-I radiation, a genetic background 
can also play a role in the development of the tumors. 
Familial DTC, or familial non-medullary thyroid cancer (FNMTC), can be a part of 
a tumor predisposition syndrome (about 5% of cases). Nowadays several well distinguished 
syndromes are known: PTEN Hamartoma tumor syndrome/Cowden syndrome (PTEN 
gene, 10q23.31), familial adenomatous polyposis (APC gene, 5q22.2), Werner syndrome 
(WRN gene, 8p12), Carney complex (PRKAR1A gene, 17q24.2), Pendred syndrome 
(SLC26A4 gene, 7q21-34) and DICER1 syndrome (DICER1 gene, 14q32.13). However, 
in the majority of FNMTC, thyroid cancer is the only manifestation within families and 
the genetic susceptibility is less well-defined (7). When defining FNMTC as the occurrence 
of the disease in two or more relatives of the index patient, about 3-9% of the DTC cases 
may have a familial origin (7,108). From a different perspective, based on data from the US, 
31-38% of family members who have two first-degree relatives with thyroid cancer, are 
likely to carry the familial trait, with the rest being sporadic cases. However, when defining 
FNMTC as the occurrence of thyroid cancer in three or more family members, 96% of 
the members of the family are likely to carry the familial trait for FNMTC (109). Other 
arguments can also be provided to support a genetic background of DTC, such as a high 
proportion of multifocality and the presence of occult tumors (13). Data collection of KIKA 
project 265 ‘The Genetic Background of Non-Medullary Paediatric Thyroid Carcinoma’ 
has recently been completed in the Netherlands. The data are currently analyzed and 
will provide information on the frequency of germline mutations in children with pediatric 
DTC, and on the yield of standard genetic screening in this patient group. 
As described in chapter 6, the genetic analyses in our cohort were performed between 
2013 and 2015, using the established methods of that time. As techniques have evolved 
over the last few years and the data of this project will be used for additional analyses in 
the above mentioned KIKA project 265, the genetic analyses will be repeated using state-
of-the-art methods. 
Organization of care
In 2015, the American Thyroid Association (ATA) published the first guidelines for children 
with DTC (110), followed by Polish guidelines (111). Although these guidelines emphasize 
collaboration and uniformity of diagnostic work-up and treatment for pediatric DTC, recent 
data have illustrated that treatment appears to be different and scattered in European 
countries and that the centralization of care is limited (112), which may have direct 
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consequences on the outcome. Although data are scarce, Youngwirth et al. showed that 
pediatric DTC patients in the US who were treated in low volume facilities were more often 
treated in a way inconsistent with the national guidelines, and more likely to be readmitted 
to the hospital in the first month after surgery, in comparison to patients treated in high-
volume facilities (92). 
This has also been the standard of care in the Netherlands as, until recently, pediatric 
DTC patients were treated by pediatric endocrinologists, adult endocrinologists or 
pediatric oncologists in a large number of centers. This resulted in a lack in uniformity 
of treatment and lack of registration of treatment and outcome. The current project has 
been the beginning of a national cooperation, and nowadays, the treatment of pediatric 
thyroid cancer is centralized in the Dutch University Medical Centers and coordinated 
by the Princess Máxima Medical Center (Dr. H.M. van Santen, pediatric endocrinologist). 
The Dutch Childhood Thyroid Carcinoma Working Group formulated recommendations 
for the organization of care for children with cancer predisposition syndromes, thyroid 
nodules and (suspected) thyroid cancer. More recently, this group has finalized 
the evidence-based Dutch pediatric guideline for the treatment of thyroid cancer (92). 
A national multidisciplinary workgroup has a web-based meeting every three months to 
discuss the diagnosis and treatment of pediatric thyroid cancer patients. Also, in 2019, 
an international cooperation on pediatric thyroid cancer was started within the European 
Reference Network (ENDO ERN). These initiatives are expected to improve care and 
outcomes for pediatric DTC patients. Prospective data registration on specific parameters 
and biobanking of tissue will ultimately further improve knowledge and care for these 
patients. The treatment of pediatric DTC has moved into a less aggressive, more patient-
tailored approach; there is a big difference in the therapy for a patient diagnosed at 
the age of 17 or 19 years. In the coming time, the patients aged between 18 and 30 years 
may be considered as a specific entity, and become the focus of prospective studies.
Conclus ions
In this thesis, we have confirmed the favorable prognosis of patients with pediatric DTC 
in terms of survival. However, we have also described frequent occurrences of post-
operative complications and late effects of treatment. The challenge remains to maintain 
the low mortality and reduce treatment-related morbidity. For this, a personalized 
approach is crucial. In our opinion, intelligent organization of care, with harmonization of 
diagnostic approach, treatment and follow-up, and centralization of care where needed, 
is vital to achieve this. The recent presentation of the new national recommendations for 
the treatment of pediatric differentiated thyroid carcinoma in the Netherlands marks an 
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